Home hero image

demonstrates 3 years (144 weeks) durable efficacy1

Through pooled data from the Cimzia arms of CIMPASI 1 and 2 trials (patients with moderate to severe plaque psoriasis).2

Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Why Cimzia image

Why is CIMZIA® different?


Cimzia is a PEGylated, FC free anti-TNF.1




efficacy teaser image

CIMZIA’s durable efficacy and long term safety profile in plaque psoriasis

With 10+ years’ experience since approval across multiple indications.1



Teaser future prof

Safety profile


Cimzia® (certolizumab pegol) has a well-established, long-term safety profile across Axial spondyloarthritis (axSpA), Plaque psoriasis (PsO), Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA).1





Making treatment choices for your female psoriasis patients of childbearing age



Discover why CIMZIA® could be a suitable treatment choice for your eligible female moderate to severe plaque psoriasis patients.1


CRIB study & CRADLE Studies


CRIB was a prospective postmarketing multicentre pharmacokinetic study designed to detect any placental transfer of Cimzia (CZP) from mothers to infants.4


CRADLE was the first industry-sponsored clinical study to evaluate Cimzia concentrations in human breast milk.

Why Cimzia image

Dosing and administration

Cimzia maintenance dosing regimen is preceded by a loading dose across all indications1










  1. CIMZIA® Summary of Product Characteristics.
  2. Gottlieb AB, et al. J Am Acad Dermatol. 2018;79(2):302-314
  3. Clowse MEB, et al. Ann Rheum Dis 2017;76(11) 1890-1896.
  4. Mariette X, et al. Annals of the Rheumatic Diseases 2018;77:228-233.


Date of preparation: October 2023


© UCB Biopharma SRL, 2021. All rights reserved.

Logo footer